Citation
80 FR 59798
Multiple canonical documents share this first-page citation.
- Prospective Grant of a Start-up Exclusive Commercial License Agreement: Development of MHC Class II Restricted T Cell Epitopes From the Cancer Antigen, NY ESO-1, for the Treatment of Human Cancers Friday, October 2, 2015 80 FR 59797
- Prospective Grant of a Start-up Exclusive Commercial License Agreement: Development of MHC Class II Restricted T Cell Epitopes From the Cancer Antigen, NY ESO-1, for the Treatment of Human Cancers Friday, October 2, 2015 80 FR 59797
- Prospective Grant of Exclusive License: Analytical Instruments Utilizing Condensation Particle Counters for the Detection and Analysis of Small Aerosol Particles Friday, October 2, 2015 80 FR 59798
- Prospective Grant of Exclusive License: Analytical Instruments Utilizing Condensation Particle Counters for the Detection and Analysis of Small Aerosol Particles Friday, October 2, 2015 80 FR 59798
- Prospective Grant of Exclusive License: Development of a ME-TARP Based Immunotherapy Friday, October 2, 2015 80 FR 59798
- Prospective Grant of Exclusive License: Development of a ME-TARP Based Immunotherapy Friday, October 2, 2015 80 FR 59798
- Federal Register Vol. 80, No.191, October 2, 2015 Friday, October 2, 2015 80 FR 59798